Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Condition: Acinetobacter Baumannii-calcoaceticus Complex; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; Bacteremia; Colistin Resistant ABC
MeSH terms: Pneumonia; Bacteremia; Pneumonia, Bacterial; Acinetobacter Infections
Intervention: Sulbactam; Durlobactam; Colistin; Imipenem/Cilastatin 500 mg/500 mg
Intervention description: 1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).; 1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h).
Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated.; Treatment for 7 days up to 14 days if clinically indicated.; 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
Intervention MeSH terms: Imipenem; Colistin; Sulbactam; Durlobactam; Cilastatin
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Masking description: Study drugs will not be masked due to logistical reasons, every attempt will be made to maintain the blind for patients, all staff at the site, and the Sponsor or its designees, except for the treatment physician and other immediate healthcare providers.
Enrollment: 207.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This is a 2-part study, with Part A being the randomized, controlled portion of the study in
      patients with ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated
      bacterial pneumonia (VABP), or bacteremia. Part B is the single-group portion of the study
      and includes ABC infections that are resistant to or have failed colistin or polymyxin B
      treatment, as detailed in the inclusion criteria.
    

Eligibility criteria:

        Inclusion Criteria:

        PART A

          1. A confirmed diagnosis of a serious infection that will require treatment with IV
             antibiotics;

          2. A known infection caused by ABC (bacteremia, HABP, VABP, VP, cUTI or AP, or surgical
             or post-traumatic wound infections) as either a single pathogen or member of a
             polymicrobial infection based on evidence from culture or, if available, rapid
             diagnostic test from a sample collected within 72 hours prior to randomization
             (HABP/VABP/VP patients), AND 1 of the following:

               1. Has received no more than 48 hrs of potentially effective (ie, Gram negative
                  coverage) antimicrobial therapy prior to the first dose of study drug;

               2. Is clinically failing prior treatment regimens

          3. APACHE II score 10 and 30 inclusive, or SOFA score between 7 and 11 inclusive, at time
             of diagnosis

          4. Expectation, in the judgment of the Investigator, that the patient will benefit from
             effective antibiotic therapy and appropriate supportive care for the anticipated
             duration of the study

          5. Women of childbearing potential (ie, not post-menopausal or surgically sterilized)
             must have a negative highly sensitive urine or serum pregnancy test before
             randomization. Participating women of childbearing potential must be willing to
             consistently use one highly effective method of contraception (ie, condom, combined
             oral contraceptive, implant, injectable, indwelling intrauterine device, or a
             vasectomized partner) from Screening until at least 30 days after administration of
             the last dose of study drug.

        PART B

        1. Has an infection (HABP, VABP, VP, bacteremia, cUTI, AP, or surgical or post-traumatic
        wound infections) caused by ABC organisms known to be resistant to colistin (defined as MIC
        ≥4 mg/L by a non-agar based method);

          1. Known to be resistant to colistin or polymyxin B; or

          2. Known intolerance to colistin; or

          3. Has myasthenia gravis or another neuromuscular syndrome(s) that contraindicates
             colistin and is not ventilated; or

          4. Has acute kidney injury and is receiving renal replacement therapy at study entry.

        Exclusion Criteria:

          1. Evidence of active concurrent pneumonia requiring additional antimicrobial treatment

          2. Presence of suspected or confirmed deep seated bacterial infections such as bacterial
             Gram negative osteomyelitis, endocarditis, or meningitis requiring prolonged therapy,
             as determined by history and/or physical examination;

          3. Sustained shock with persisting hypotension requiring vasopressors to maintain mean
             arterial pressure (MAP) ≥ 60 mmHg;

          4. Pregnant or breastfeeding women;

          5. Receiving peritoneal dialysis;

          6. Requirement for continuing treatment with probenecid, methotrexate, ganciclovir,
             valproic acid, or divalproex sodium during the study;

          7. Evidence of significant hepatic disease or dysfunction, including known acute viral
             hepatitis, hepatic cirrhosis, hepatic failure, chronic ascites, or hepatic
             encephalopathy;